Sensor Dot
DeviceMultimodal (EEG, ECG, EMG and motion) seizure monitoring with Sensor Dot to complement EMU-based video-EEG monitoring (EMU Phase), and optional home-based seizure diary logging (Home Phase).
NCT Number: NCT04284072
Clinically validate a biopotential and motion recording wearable device (Byteflies Sensor Dot) for detection of epileptic seizures in the epilepsy monitoring unit (EMU) and at home.
Looking for future studies?
Notify Me4 year and older
All sexes
Interventional
Not applicable
University Hospitals Leuven, department of Neurology, Leuven, Belgium
Subjects with refractory epilepsy who are admitted to the Epilepsy Monitoring Unit (EMU) for clinically-indicated long-term video-EEG assessment will be simultaneously monitored with Sensor Dots to record electroencephalographic (EEG), electrocardiographic (ECG), electromyographic (EMG), and motion signals.
A subset of subjects will continue using Sensor Dot devices at home (Home Phase) after completing the EMU Phase.
The data recorded by Sensor Dots will be used to: 1) annotate epileptic seizures, which will be compared to the annotations made as part of routine EMU monitoring and seizure diaries kept at home, and 2) to develop seizure detection algorithms. The data collected as part of this study will not be used to influence clinical decision making.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Multimodal (EEG, ECG, EMG and motion) seizure monitoring with Sensor Dot to complement EMU-based video-EEG monitoring (EMU Phase), and optional home-based seizure diary logging (Home Phase).
Time frame: up to two weeks
F1-score as determined by expert reviewers
Time frame: up to two weeks
F1-score as determined by expert reviewers
Time frame: up to two weeks
F1-score as determined by expert reviewers
Time frame: up to two weeks
F1-score as determined by expert reviewers
Time frame: up to two weeks
F1-score as determined by expert reviewers
Time frame: up to two weeks
F1-score as determined by expert reviewers
Time frame: up to two weeks
We will assess the usability of the device as perceived by users (patients and healthcare personnel) via surveys
Time frame: up to two weeks
From the Sensor Dot data, we will be able to assess seizure duration
Time frame: up to two weeks
We will asses usability of the electronic seizure diary
Time frame: 2 years
We will use the collected data and seizure annotations to develop algorithms to automatically detect epileptic seizures. We plan to evaluate how accurate these new automated seizure detection algorithms are.
Time frame: up to 2 weeks
Accuracy as determined by expert reviewers
Time frame: up to 2 weeks
We will assess the technical performance of the device by comparing the actual length of recorded data against the expected recording length, and what percentage of the data is high quality enough to make seizure annotations.
Universitaire Ziekenhuizen KU Leuven
Other
A Multicenter Study to Examine Clinical Scenarios for Long-term Monitoring of Epileptic Seizures With a Wearable Biopotential Technology
Acronym: SeizeIT2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06714448
Brain Diseases, Central Nervous System Diseases
Chilly-Mazarin, France
View Trial DetailsNCT02886650
Brain Diseases, Central Nervous System Diseases
Paris, France
View Trial DetailsNCT04999046
Brain Diseases, Central Nervous System Diseases
Taipei, Taiwan
View Trial DetailsNCT04770337
Brain Diseases, Central Nervous System Diseases
Phoenix, Arizona, United States
View Trial Details